Standard of Care
Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market
Takeda; Phase 3; narcolepsy type 1; oveporexton; TAK-861; orexin agonist; multibillion-dollar market; clinical trial results; first mover; standard of care
ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study
cabenuva, Daily, Standard of Care, Adherence (attribute), HIV, Participant, daily